Compare C & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | C | NVO |
|---|---|---|
| Founded | 1812 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1B | 199.4B |
| IPO Year | 2025 | 2001 |
| Metric | C | NVO |
|---|---|---|
| Price | $137.70 | $46.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $134.94 | $51.00 |
| AVG Volume (30 Days) | 5.2M | ★ 9.7M |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | 1.88% | ★ 3.19% |
| EPS Growth | ★ 17.68 | N/A |
| EPS | ★ 6.99 | N/A |
| Revenue | ★ $85,225,000,000.00 | N/A |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $3.63 | $3.70 |
| P/E Ratio | $19.75 | ★ $13.60 |
| Revenue Growth | ★ 5.04 | N/A |
| 52 Week Low | $93.66 | $35.12 |
| 52 Week High | $147.96 | $64.16 |
| Indicator | C | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 52.05 |
| Support Level | $126.15 | $43.25 |
| Resistance Level | $140.07 | $48.23 |
| Average True Range (ATR) | 2.64 | 0.98 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 75.16 | 63.82 |
Citigroup is a global financial powerhouse that orchestrates the movement of $5 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm remains a leader on the global stage, servicing 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, steps have been taken to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.